# A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty

> **NCT06070532** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cellcolabs Clinical LTD.** · enrollment: 12 (estimated)

## Conditions studied

- Frailty

## Interventions

- **BIOLOGICAL:** Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)

## Key facts

- **NCT ID:** NCT06070532
- **Lead sponsor:** Cellcolabs Clinical LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2027-01-10
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06070532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06070532, "A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06070532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*